| Authors: |
Mandalà M; Unit of Medical Oncology, University of Perugia, Perugia, Italy. Electronic address: mario.mandala@unipg.it., Amaral T; Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Sergi MC; Unit of Medical Oncology, 'Mons. A.R. Dimiccoli' Hospital, Asl BT, Viale Ippocrate, 15, Barletta, BT 70051, Italy., Rasch ML; Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Benannoune N; Gustave Roussy Cancer Campus, Villejuif, France., Serra P; The University of Manchester, Oxford Rd, Manchester M13 9PL, UK., Vitale MG; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione 'G. Pascale' Napoli, Naples, Italy., Giannarelli D; Epidemiology and Biostatistics, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy., Arance AM; Hospital Clínic Barcelona and IDIBAPS, Barcelona 08036, Spain., Couselo EM; Department of medical oncology. Vall d'Hebron Hospital, Barcelona, Spain & Vall d'Hebron Institute of oncology (VHIO), Barcelona, Spain., Neyns B; Department of Medical Oncology, UZ Brussel, Brussels, Belgium., Dirven I; Department of medical oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Tucci M; Medical Oncology Unit, University of Bari Aldo Moro, Policlinico Hospital of Bari, Bari 70124, Italy., Guida M; Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori 'Giovanni Paolo II', Bari, Italy., Spagnolo F; IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy., Rossi E; Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy., Queirolo P; IEO European Institute of Oncology, IRCCS, Milan, Italy., Quaglino P; Department of Dermatology, University of Turin, Turin, Italy., Depenni R; University of Modena and Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy., Placzke J; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Giacomo AMD; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy., Del Vecchio M; Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Indini A; Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Silva IPD; Melanoma Institute Australia, University of Sydney, and Blacktown Hospital, Sydney, New South Wales, Australia., Menzies AM; Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Hong A; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales 2050, Australia; Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Australia., Lorigan P; The University of Manchester, Oxford Rd, Manchester M13 9PL, UK., Long GV; Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Robert C; Gustave Roussy and Paris-Saclay University, Villejuif, France., Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione 'G. Pascale' Napoli, Naples, Italy. |
